BRUCE C. COZADD - Corporate Board Profile

CERUS CORP

Filing Date	Source Excerpt
2010-04-23	Bruce C. Cozadd, 46, has served as a member of our Board since November 2001. The Nominating and Corporate Governance concluded that Mr. Cozadd continues to be a valuable member of the Board in part due to his extensive financial management expertise as the former Chief Financial Officer of ALZA Corporation and his industry expertise as the Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table shows for the fiscal year ended December 31, 2009 certain information with respect to the compensation of all non-employee directors of the Company: ... Bruce C. Cozadd 75,000 28,483 0 0 103,483
2011-04-22	Bruce C. Cozadd, 47, has served as a member of our Board since November 2001. The Audit Committee comprises three (3) directors: Messrs. Anderson, Cozadd (Chair) and Rohn, all of whom were on the Audit Committee for all of 2010. The Compensation Committee of the Board comprises three (3) directors: Mr. Cassin (chair), Mr. Cozadd and Ms. Schulze, all of whom were on the Compensation Committee for all of 2010. The Nominating and Corporate Governance Committee comprises five (5) directors: Messrs. Cassin (Chair), Anderson, Cozadd, Rohn and Ms. Schulze, all of whom were on the Nominating and Corporate Governance Committee for all of 2010. For the year ended December 31, 2010, Bruce Cozadd received $60,000 in fees and $18,240 in option awards totaling $78,240.
2013-04-29	Bruce C. Cozadd, 49, has served as a member of our Board since November 2001. The Nominating and Corporate Governance Committee concluded that Mr. Cozadd should continue to serve as a member of the Board in part due to his extensive financial management expertise as the former Chief Financial Officer of ALZA Corporation and his industry expertise as the Chairman and Chief Executive Officer of Jazz Pharmaceuticals plc. This expertise has also led the Board to determine that he is an "audit committee financial expert" as defined the by the SEC. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table provides membership and meeting information for fiscal 2012 for each of the Board committees: ... Bruce C. Cozadd: Audit Committee (Chair), Compensation Committee, Nominating and Corporate Governance Committee. ... The Compensation Committee is composed of three directors: Mr. Cassin, Mr. Cozadd and Ms. Schulze (Chair). ... The Nominating and Corporate Governance Committee consists of five directors: Messrs. Cassin (Chair), Anderson, Cozadd, Swisher and Ms. Schulze.
2014-04-30	Bruce C. Cozadd, 50, has served as a member of our Board since November 2001. The Nominating and Corporate Governance Committee and the Board concluded that Mr. Cozadd should continue to serve as a member of the Board in part due to his extensive financial management expertise as the former Chief Financial Officer of ALZA Corporation and his industry expertise as the Chairman and Chief Executive Officer of Jazz Pharmaceuticals plc. This expertise has also led the Board to determine that he is an "audit committee financial expert" as defined the by the SEC. The Board also believes that because Mr. Cozadd has been a director since 2001, he brings historic knowledge and continuity to the Board. Mr. Cozadd is a co-founder of Jazz Pharmaceuticals, Inc. and has served as its Chairman and Chief Executive Officer since April 2009. In January 2012, Mr. Cozadd became the Chairman and Chief Executive Officer of Jazz Pharmaceuticals plc, the successor to Jazz Pharmaceuticals, Inc. From 2003 until April 2009, he served as Executive Chairman of Jazz Pharmaceuticals, Inc. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing and prior to that as Chief Financial Officer and Vice President, Corporate Planning and Analysis. Previously, Mr. Cozadd was a member of the health care investment banking team at Smith Barney, Harris Upham & Co. He serves on the boards of Jazz Pharmaceuticals plc, Threshold Pharmaceuticals, a biotechnology company, and The Nueva School, a non-profit organization. He received a B.S. in molecular biophysics & biochemistry and economics from Yale University and an M.B.A. from the Stanford Graduate School of Business. The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2013 for each of the Board committees: Bruce C. Cozadd: Audit Committee (Chair), Compensation Committee, Nominating and Corporate Governance Committee. The Compensation Committee reviews director compensation on a periodic basis. For the year ended December 31, 2013, the Amended Policy provides that each director, other than the Chair of the Board, who is not also one of our officers or employees, will be compensated for his or her services as a director at the rate of $35,000 per year. The Chair of the Board will receive an annual retainer of $57,500 per year. The annual retainer is paid to our non-employee directors in equal quarterly installments. In addition to the annual retainer, the chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committees will receive an additional annual retainer of $26,000, $12,500 and $10,000, respectively. Each other member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee who is not one of our employees will receive an annual retainer of $13,000, $8,000 and $6,000, respectively. Bruce C. Cozadd's total compensation for 2013 was $119,420.
2015-04-30	Bruce C. Cozadd, 51, has served as a member of our Board since November 2001. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2014 for each of the Board committees: Bruce C. Cozadd Audit X, Compensation * (Chair), Nominating and Corporate Governance X. ... The following table shows for the fiscal year ended December 31, 2014 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2014. ... Bruce C. Cozadd Fees Earned or Paid in Cash($) 74,000 Option Awards($) 107,065 Total($) 181,065.
2016-04-29	Bruce C. Cozadd, 52, has served as a member of our Board since November 2001. The Audit Committee is currently composed of three directors: Messrs. Anderson, Cozadd (Chair) and Swisher. The Compensation Committee is currently composed of three directors: Mr. Cozadd, Ms. Schulze (Chair) and Dr. Witney. The Nominating and Corporate Governance Committee currently consists of two directors: Messrs. Anderson (Chair) and Swisher.
2017-04-28	Bruce C. Cozadd, 53, has served as a member of our Board since November 2001. ... Mr. Cozadd is a co-founder of Jazz Pharmaceuticals, Inc. and has served as its Chairman and Chief Executive Officer since April 2009. ... The Audit Committee is currently composed of three directors: Messrs. Anderson, Cozadd (Chair) and Swisher, all of whom were on the Audit Committee for all of 2016. ... The Compensation Committee is currently composed of three directors: Mr. Cozadd, Ms. Schulze (Chair) and Dr. Witney, all of whom were on the Compensation Committee for all of 2016. ... For the year ended December 31, 2016, each director, other than the Chair of the Board, who is not also one of our officers or employees, was compensated for his or her services as a director at the rate of $40,000 per year. The Chair of the Board received an annual retainer of $62,500 per year. ... Bruce C. Cozadd Fees Earned or Paid in Cash($) 74,000, Option Awards($) 61,611, Stock Awards($) 61,609, Total($) 197,220.
2018-04-27	Bruce C. Cozadd retired from the Board and all of its committees effective January 3, 2018; served as Chair of the Audit Committee through October 2017. ... For the year ended December 31, 2017, each director, who is not also one of our officers or employees, other than the Chair of the Board, was compensated for his or her services as a director at the rate of $40,000 per year. ... Bruce C. Cozadd received total compensation of $163,202 in 2017.

Jazz Pharmaceuticals plc

Filing Date	Source Excerpt
2015-06-10	He received a B.S. from Yale University and a M.B.A. from the Stanford Graduate School of Business. As our Chief Executive Officer, he brings to our board of directors a detailed knowledge of our business.
2016-06-20	Mr. Cozadd has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He co-founded Jazz Pharmaceuticals, Inc. and has served (and continues to serve) as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.’s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. He serves on the boards of Cerus Corporation, a biomedical products company, Threshold Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, The Nueva School, a non-profit organization, and SFJAZZ, a non-profit organization. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
2017-06-20	Mr. Cozadd has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He co-founded Jazz Pharmaceuticals, Inc. and has served (and continues to serve) as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation, he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the board of directors and compensation committee of Cerus Corporation, a biomedical products company, where he serves as Chair of the audit committee. He also serves on the board of directors and compensation committee of Threshold Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, but his tenure is expected to conclude at the effective time of the merger contemplated by the agreement and plan of merger and reorganization between Threshold Pharmaceuticals, Inc. and Molecular Templates, Inc., which is expected to close in the third quarter of 2017. Mr. Cozadd also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
2018-06-15	Mr. Cozadd previously held roles including Chief Financial Officer and Vice President, Corporate Planning and Analysis. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. As our Chief Executive Officer, he brings to our board of directors a detailed knowledge of our business.
2019-06-14	Mr. Cozadd has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He co-founded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009.
2020-06-12	Bruce C. Cozadd has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012, and from October 2019 through March 2020, he served as our interim principal financial officer. Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.'s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation, he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
2021-06-11	Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
2021-08-30	Bruce C. Cozadd included in the list of directors with no indication of software or technical background.
2022-06-13	As a co-founder and our Chief Executive Officer of over 10 years, he brings to our board a deep and comprehensive knowledge of our business, as well as shareholder-focused insight into effectively executing the companys strategy and business plans to maximize shareholder value.
2023-06-16	Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. and has served as Chairperson and Chief Executive Officer. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
2024-06-14	Mr. Cozadd’s extensive leadership experience having served as co-founder and our CEO for over 10 years and having served previously as Chairperson and CEO of Jazz Pharmaceuticals, Inc.